<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>oncology</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>oncology | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Low Booster uptake in cancer patients despite health benefits
Authors: Figueiredo, J. C.; Levy, J. A.; Choi, S. Y.; Xu, A. M.; Merin, N. M.; Hamid, O.; Lemos, T.; Nguyen, N.; Nadri, M.; Gonzalez, A.; Mahov, S.; Darrah, J. M.; Gong, J.; Paquette, R. L.; Mita, A. C.; Vescio, R. A.; Salvy, S. J.; Mehmi, I.; Hendifar, A. E.; Natale, R. B.; Tourtellotte, W. G.; Ramanujan, V. K.; Huynh, C.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/oncology/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="oncology" />
<meta property="og:description" content="Low Booster uptake in cancer patients despite health benefits
Authors: Figueiredo, J. C.; Levy, J. A.; Choi, S. Y.; Xu, A. M.; Merin, N. M.; Hamid, O.; Lemos, T.; Nguyen, N.; Nadri, M.; Gonzalez, A.; Mahov, S.; Darrah, J. M.; Gong, J.; Paquette, R. L.; Mita, A. C.; Vescio, R. A.; Salvy, S. J.; Mehmi, I.; Hendifar, A. E.; Natale, R. B.; Tourtellotte, W. G.; Ramanujan, V. K.; Huynh, C." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/oncology/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-11-01T10:38:40+00:00" />
<meta property="article:modified_time" content="2023-11-01T10:38:40+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="oncology"/>
<meta name="twitter:description" content="Low Booster uptake in cancer patients despite health benefits
Authors: Figueiredo, J. C.; Levy, J. A.; Choi, S. Y.; Xu, A. M.; Merin, N. M.; Hamid, O.; Lemos, T.; Nguyen, N.; Nadri, M.; Gonzalez, A.; Mahov, S.; Darrah, J. M.; Gong, J.; Paquette, R. L.; Mita, A. C.; Vescio, R. A.; Salvy, S. J.; Mehmi, I.; Hendifar, A. E.; Natale, R. B.; Tourtellotte, W. G.; Ramanujan, V. K.; Huynh, C."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "oncology",
      "item": "https://trxiv.yorks0n.com/posts/oncology/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "oncology",
  "name": "oncology",
  "description": "Low Booster uptake in cancer patients despite health benefits\nAuthors: Figueiredo, J. C.; Levy, J. A.; Choi, S. Y.; Xu, A. M.; Merin, N. M.; Hamid, O.; Lemos, T.; Nguyen, N.; Nadri, M.; Gonzalez, A.; Mahov, S.; Darrah, J. M.; Gong, J.; Paquette, R. L.; Mita, A. C.; Vescio, R. A.; Salvy, S. J.; Mehmi, I.; Hendifar, A. E.; Natale, R. B.; Tourtellotte, W. G.; Ramanujan, V. K.; Huynh, C.",
  "keywords": [
    
  ],
  "articleBody": " Low Booster uptake in cancer patients despite health benefits\nAuthors: Figueiredo, J. C.; Levy, J. A.; Choi, S. Y.; Xu, A. M.; Merin, N. M.; Hamid, O.; Lemos, T.; Nguyen, N.; Nadri, M.; Gonzalez, A.; Mahov, S.; Darrah, J. M.; Gong, J.; Paquette, R. L.; Mita, A. C.; Vescio, R. A.; Salvy, S. J.; Mehmi, I.; Hendifar, A. E.; Natale, R. B.; Tourtellotte, W. G.; Ramanujan, V. K.; Huynh, C. A.; Sobhani, K.; Reckamp, K. L.; Merchant, A. A.\nScore: 2.8, Published: 2023-10-26 DOI: 10.1101/2023.10.25.23297483\nPatients with cancer are at increased risk of death from COVID-19 and have reduced immune responses to SARS-CoV2 vaccines, necessitating regular boosters. We performed comprehensive chart reviews, surveys of patients attitudes, serology for SARS-CoV-2 antibodies and T-cell receptor (TCR) {beta} sequencing for cellular responses on a cohort of 982 cancer patients receiving active cancer therapy accrued between November-3-2020 and Mar-31-2023. We found that 92{middle dot}3% of patients received the primer vaccine, 70{middle dot}8% received one monovalent booster, but only 30{middle dot}1% received a bivalent booster. Booster uptake was lower under age 50, and among African American or Hispanic patients. Nearly all patients seroconverted after 2+ booster vaccinations (\u003e99%) and improved cellular responses, demonstrating that repeated boosters could overcome poor response to vaccination. Receipt of booster vaccinations was associated with a lower risk of all-cause mortality (HR=0{middle dot}61, P=0{middle dot}024). Booster uptake in high-risk cancer patients remains low and strategies to encourage booster uptake are needed. HighlightsO_LICOVID-19 booster vaccinations increase antibody levels and maintain T-cell responses against SARS-CoV-2 in patients receiving various anti-cancer therapies C_LIO_LIBooster vaccinations reduced all-cause mortality in patients C_LIO_LIA significant proportion of patients remain unboosted and strategies are needed to encourage patients to be up-to-date with vaccinations C_LI\nResponse to immune checkpoint inhibition is associated with the gut microbiome in advanced KRAS-mutated non-small cell lung cancer\nAuthors: Hiddinga, B. I.; Bolte, L. A.; van der Leest, P.; Hijmering-Kappelle, L. B.; van der Wekken, A. J.; Schuuring, E.; Gacesa, R.; Hospers, G. A.; Weersma, R. K.; Bjork, J. R.; Hiltermann, T. J. N.\nScore: 1.5, Published: 2023-10-30 DOI: 10.1101/2023.10.30.23297712\nBackground: KRAS-mutated non-small cell lung cancer (NSCLC) is associated with a poor prognosis to standard therapies. Despite advances of immune checkpoint inhibitors (ICIs), not all patients show durable responses. In this study, we aim to identify associations between ICI-response and the gut microbiome in patients with KRAS-mutated NSCLC. Methods: We performed shotgun metagenomic sequencing of stool samples collected before ICI initiation from 33 patients with KRAS-mutated NSCLC. Microbiome composition within (-diversity) and between samples ({beta}-diversity) was calculated using Shannon diversity index and principal component analysis on Aitchison distances, respectively. A Bayesian logistic-normal regression model (Pibble) was implemented to identify associations between gut microbial features and disease control rate (DCR), progression free survival at 12 months (PFS12) and immune related adverse events (irAEs), adjusting for ICI-regimen, metastatic disease stage, age, sex and BMI. Results: Responders were enriched with several saccharolytic species, including Agathobaculum butyriciproducens, Fusicatenibacter saccharivorans, Bifidobacterium longum and Eubacterium ramulus. Non-responders harbored higher abundances of several Bacteroides and Blautia species. Patients unaffected by irAEs demonstrated higher abundances of biotin and butyrate synthesis pathways. Development of irAEs was associated with higher Alistipes finegoldii, Bifidobacterium longum and Bacteroides uniformis abundance. No differences were observed between responders and non-responders in Shannon diversity index (P=0.69) and overall microbial composition (P=0.82). Conclusions: We show gut microbial species and pathways that are differentially abundant between responders and non-responders to ICI in the setting of KRAS-mutated NSCLC. We find overlap with microbial signatures of response to ICI in other tumor types, potentially reflecting tumor-independent microbial mechanisms.\n",
  "wordCount" : "594",
  "inLanguage": "en",
  "datePublished": "2023-11-01T10:38:40Z",
  "dateModified": "2023-11-01T10:38:40Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/oncology/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      oncology
    </h1>
    <div class="post-meta">&lt;span&gt;updated on November 1, 2023&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.10.25.23297483">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.10.25.23297483" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.10.25.23297483">
        <p class="paperTitle">Low Booster uptake in cancer patients despite health benefits</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.10.25.23297483" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.10.25.23297483" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Figueiredo, J. C.; Levy, J. A.; Choi, S. Y.; Xu, A. M.; Merin, N. M.; Hamid, O.; Lemos, T.; Nguyen, N.; Nadri, M.; Gonzalez, A.; Mahov, S.; Darrah, J. M.; Gong, J.; Paquette, R. L.; Mita, A. C.; Vescio, R. A.; Salvy, S. J.; Mehmi, I.; Hendifar, A. E.; Natale, R. B.; Tourtellotte, W. G.; Ramanujan, V. K.; Huynh, C. A.; Sobhani, K.; Reckamp, K. L.; Merchant, A. A.</p>
        <p class="info">Score: 2.8, Published: 2023-10-26 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.10.25.23297483' target='https://doi.org/10.1101/2023.10.25.23297483'> 10.1101/2023.10.25.23297483</a></p>
        <p class="abstract">Patients with cancer are at increased risk of death from COVID-19 and have reduced immune responses to SARS-CoV2 vaccines, necessitating regular boosters. We performed comprehensive chart reviews, surveys of patients attitudes, serology for SARS-CoV-2 antibodies and T-cell receptor (TCR) {beta} sequencing for cellular responses on a cohort of 982 cancer patients receiving active cancer therapy accrued between November-3-2020 and Mar-31-2023. We found that 92{middle dot}3% of patients received the primer vaccine, 70{middle dot}8% received one monovalent booster, but only 30{middle dot}1% received a bivalent booster. Booster uptake was lower under age 50, and among African American or Hispanic patients. Nearly all patients seroconverted after 2&#43; booster vaccinations (&gt;99%) and improved cellular responses, demonstrating that repeated boosters could overcome poor response to vaccination. Receipt of booster vaccinations was associated with a lower risk of all-cause mortality (HR=0{middle dot}61, P=0{middle dot}024). Booster uptake in high-risk cancer patients remains low and strategies to encourage booster uptake are needed.

HighlightsO_LICOVID-19 booster vaccinations increase antibody levels and maintain T-cell responses against SARS-CoV-2 in patients receiving various anti-cancer therapies
C_LIO_LIBooster vaccinations reduced all-cause mortality in patients
C_LIO_LIA significant proportion of patients remain unboosted and strategies are needed to encourage patients to be up-to-date with vaccinations
C_LI</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.10.30.23297712">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.10.30.23297712" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.10.30.23297712">
        <p class="paperTitle">Response to immune checkpoint inhibition is associated with the gut microbiome in advanced KRAS-mutated non-small cell lung cancer</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.10.30.23297712" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.10.30.23297712" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Hiddinga, B. I.; Bolte, L. A.; van der Leest, P.; Hijmering-Kappelle, L. B.; van der Wekken, A. J.; Schuuring, E.; Gacesa, R.; Hospers, G. A.; Weersma, R. K.; Bjork, J. R.; Hiltermann, T. J. N.</p>
        <p class="info">Score: 1.5, Published: 2023-10-30 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.10.30.23297712' target='https://doi.org/10.1101/2023.10.30.23297712'> 10.1101/2023.10.30.23297712</a></p>
        <p class="abstract">Background: KRAS-mutated non-small cell lung cancer (NSCLC) is associated with a poor prognosis to standard therapies. Despite advances of immune checkpoint inhibitors (ICIs), not all patients show durable responses. In this study, we aim to identify associations between ICI-response and the gut microbiome in patients with KRAS-mutated NSCLC. Methods: We performed shotgun metagenomic sequencing of stool samples collected before ICI initiation from 33 patients with KRAS-mutated NSCLC. Microbiome composition within (-diversity) and between samples ({beta}-diversity) was calculated using Shannon diversity index and principal component analysis on Aitchison distances, respectively. A Bayesian logistic-normal regression model (Pibble) was implemented to identify associations between gut microbial features and disease control rate (DCR), progression free survival at 12 months (PFS12) and immune related adverse events (irAEs), adjusting for ICI-regimen, metastatic disease stage, age, sex and BMI. Results: Responders were enriched with several saccharolytic species, including Agathobaculum butyriciproducens, Fusicatenibacter saccharivorans, Bifidobacterium longum and Eubacterium ramulus. Non-responders harbored higher abundances of several Bacteroides and Blautia species. Patients unaffected by irAEs demonstrated higher abundances of biotin and butyrate synthesis pathways. Development of irAEs was associated with higher Alistipes finegoldii, Bifidobacterium longum and Bacteroides uniformis abundance. No differences were observed between responders and non-responders in Shannon diversity index (P=0.69) and overall microbial composition (P=0.82). Conclusions: We show gut microbial species and pathways that are differentially abundant between responders and non-responders to ICI in the setting of KRAS-mutated NSCLC. We find overlap with microbial signatures of response to ICI in other tumor types, potentially reflecting tumor-independent microbial mechanisms.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        · Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
